MedPath

Felbamate

Generic Name
Felbamate
Brand Names
Felbatol
Drug Type
Small Molecule
Chemical Formula
C11H14N2O4
CAS Number
25451-15-4
Unique Ingredient Identifier
X72RBB02N8

Overview

Felbamate is an anticonvulsant drug used in the treatment of epilepsy. In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization). Alternatively, it is used to treat partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites.

Background

Felbamate is an anticonvulsant drug used in the treatment of epilepsy. In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization). Alternatively, it is used to treat partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites.

Indication

For use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.

Associated Conditions

  • Refractory Partial Onset Seizures
  • Status Epilepticus
  • Refractory Lennox-Gastaut syndrome

FDA Approved Products

Felbamate
Manufacturer:Bryant Ranch Prepack
Route:ORAL
Strength:400 mg in 1 1
Approved: 2018/09/04
NDC:63629-1937
Felbamate
Manufacturer:Bryant Ranch Prepack
Route:ORAL
Strength:600 mg in 1 1
Approved: 2018/09/04
NDC:63629-1944
Felbamate
Manufacturer:Novitium Pharma LLC
Route:ORAL
Strength:600 mg in 5 mL
Approved: 2022/09/13
NDC:70954-051
Felbamate
Manufacturer:Wallace Pharmaceuticals Inc.
Route:ORAL
Strength:400 mg in 1 1
Approved: 2018/02/21
NDC:51525-0430
Felbamate
Manufacturer:Alvogen Inc.
Route:ORAL
Strength:400 mg in 1 1
Approved: 2015/01/29
NDC:47781-627

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath